Literature DB >> 17928742

Life style-related diseases of the digestive system: colorectal cancer as a life style-related disease: from carcinogenesis to medical treatment.

Hirokazu Takahashi1, Kyoko Yoneda, Ayako Tomimoto, Hiroki Endo, Toshio Fujisawa, Hiroshi Iida, Hironori Mawatari, Yuichi Nozaki, Tamon Ikeda, Tomoyuki Akiyama, Masato Yoneda, Masahiko Inamori, Yasunobu Abe, Satoru Saito, Atsushi Nakajima, Hitoshi Nakagama.   

Abstract

Life style-related diseases are associated with an increased risk of colorectal cancer (CRC). Recently, an association has been demonstrated between obesity and CRC. CRC has been associated with markers of insulin or glucose control, and insulin resistance might be the unifying mechanism by which several risk factors affect colorectal carcinogenesis. We evaluated the association between the number of aberrant crypt foci (ACF) and obesity, insulin resistance, hyperlipidemia, and other factors of life style-related disease. As a result, age, body mass index (BMI), waist circumference, and visceral fat obesity were significantly associated with the number of ACF. These results suggest that visceral fat obesity is an important target for CRC prevention. Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor superfamily and is highly expressed in CRC. PPARgamma ligand administration for 1 to 8 months significantly reduced the number of ACF in human subjects. PPARgamma ligand is a promising candidate as a chemopreventive agent. Further investigation is needed to elucidate these mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928742     DOI: 10.1254/jphs.fm0070022

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  7 in total

1.  Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

Authors:  Helen Swede; Thomas E Rohan; Herbert Yu; Joseph C Anderson; Richard G Stevens; Jane Brokaw; Joel Levine; Bruce M Brenner; Carl D Malchoff; Valerie B Duffy; Devon C Pleau; Daniel W Rosenberg
Journal:  Cancer Causes Control       Date:  2008-12-09       Impact factor: 2.506

2.  Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.

Authors:  Takuma Higurashi; Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Hiroshi Iida; Takashi Uchiyama; Akiko Ezuka; Shiori Uchiyama; Eiji Yamada; Hidenori Ohkubo; Eiji Sakai; Shin Maeda; Satoshi Morita; Yutaka Natsumeda; Hajime Nagase; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2012-09-19       Impact factor: 4.430

3.  C57BL/KsJ-db/db-Apc mice exhibit an increased incidence of intestinal neoplasms.

Authors:  Kazuya Hata; Masaya Kubota; Masahito Shimizu; Hisataka Moriwaki; Toshiya Kuno; Takuji Tanaka; Akira Hara; Yoshinobu Hirose
Journal:  Int J Mol Sci       Date:  2011-11-18       Impact factor: 5.923

4.  Occurrence of colorectal aberrant crypt foci depending on age and dietary patterns of patients.

Authors:  Marek Kowalczyk; Marcin Orłowski; Piotr Siermontowski; Dariusz Mucha; Krzysztof Zinkiewicz; Waldemar Kurpiewski; Ewa Zieliński; Iwona Kowalczyk; Agnieszka Pedrycz
Journal:  BMC Cancer       Date:  2018-02-21       Impact factor: 4.430

5.  Hypothesis: Mutations and Immunosurveillance in Obesity-Associated Colorectal Cancer.

Authors:  Darina Lazarova; Michael Bordonaro
Journal:  J Cancer       Date:  2022-08-08       Impact factor: 4.478

6.  Hypothesis: Obesity Is Associated with a Lower Mutation Threshold in Colon Cancer.

Authors:  Michael Bordonaro; Darina Lazarova
Journal:  J Cancer       Date:  2015-07-15       Impact factor: 4.207

7.  The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.

Authors:  Takuma Higurashi; Jun Arimoto; Keiichi Ashikari; Tomohiro Takatsu; Noboru Misawa; Tsutomu Yoshihara; Tetsuya Matsuura; Akiko Fuyuki; Hidenori Ohkubo; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2020-08-17       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.